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Abstract Lysophosphatidylcholine (lyso-PC), a polar phospho-
lipid increased in atherogenic lipoproteins and atherosclerotic
lesions, has been shown to induce transcription of a variety of
endothelial genes relevant to atherogenesis. Lyso-PC has been
shown to activate c-jun N-terminal kinase (JNK) and activator
protein 1 (AP-1) and thereby stimulate transcription of the c-jun
gene. Here we provide evidence that lyso-PC can phosphorylate
cyclic AMP responsive element binding protein (CREB) and
thereby activate the jun2 12-O-tetradecanoylphorbol 13-acetate
response element (jun2TRE) site of the c-jun promoter, which
appears to be the major molecular mechanism involved in lyso-
PC-induced c-jun gene expression in cultured bovine aortic
endothelial cells (BAEC). Transient transfection of BAEC with a
1.6-kbp c-jun promoter and luciferase reporter fusion gene
resulted in a 12.9-fold increase in luciferase activity by lyso-PC
treatment. Serial deletion mutation in c-jun promoter and
luciferase reporter gene assay revealed that the 5P promoter
region between nucleotide numbers 3268 and 3127, which
contains a jun2TRE binding sequence, was most crucial for lyso-
PC-induced transcription. The 5P promoter region between 376
and 327, which contains an AP-1 site, also affected lyso-PC-
induced transcription of the c-jun gene. Point mutation in the
jun2TRE site reduced lyso-PC-induced transcription of the c-jun
promoter-luciferase fusion gene by a 70.3% decrease in c-jun
promoter activity. Electrophoretic mobility shift assays showed
increased binding of 32P-labeled oligonucleotides with jun2TRE
in nuclear extracts isolated from lyso-PC-treated BAEC, which
was abolished or supershifted by anti-CREB antibody. Immuno-
blotting with anti-phosphorylated CREB antibody showed rapid
phosphorylation of this protein after lyso-PC treatment. These
results indicate that lyso-PC phosphorylates CREB, which was
then bound to the jun2TRE site of the c-jun promoter and
activated transcription. Activation of jun2TRE may play a key
role in the transcriptional activation of c-jun as well as other
endothelial genes depending upon these transcription factors.
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1. Introduction
Lysophosphatidylcholine (lyso-PC) is a prominent phos-
pholipid component of atherogenic lipoproteins and athero-
sclerotic lesions [1^3]. Lyso-PC is also generated in wounds
and in£ammatory lesions by actions of extracellular phospho-
lipase A activities [4]. Recent reports have shown that lyso-PC
can induce expression of various genes [5^11] in cultured vas-
cular endothelial cells and other cell types in addition to its
inhibitory e¡ects on endothelial-dependent vasorelaxation [12]
and endothelial cell migration [13].
Lyso-PC has been shown to mobilize intracellular calcium
[14], activate protein kinase C [15], disrupt a receptor-G pro-
tein coupling [16], elevate intracellular cyclic AMP [17], acti-
vate mitogen-activated protein kinases (MAP kinases), such as
extracellular signal-regulated protein kinase (ERK) [18] and
JNK [18,19], induce activator protein 1 (AP-1) DNA binding
[20], activate NF-UB [20], and stimulate tyrosine phospho-
rylation of platelet endothelial cell adhesion molecule-1 (PE-
CAM-1) [21] in cultured vascular endothelial cells. Further-
more, reagents that increase intracellular cyclic AMP, such as
forskolin and dibutyryl cyclic AMP, suppress lyso-PC-induced
expression of platelet-derived growth factor (PDGF)-B chain
and intercellular cell adhesion molecule-1 (ICAM-1) [21].
C-Jun, as well as c-Fos, can be phosphorylated in response
to biological stimuli and bind to AP-1 sites in promoters,
thereby activating gene transcription [23]. Transcriptional reg-
ulation of the c-jun gene by ischemic reperfusion in rat kidney
cells has been shown to depend upon the jun2 12-O-tetrade-
canoylphorbol 13-acetate response element (jun2TRE) site in
the c-jun promoter [24]. To gain insight into the molecular
mechanisms involved in lyso-PC-induced gene transcription,
we have explored the transcriptional regulatory mechanisms
of the c-jun gene as a model. Here, we provide evidence that
lyso-PC-induced transcription of the c-jun gene depends
mainly upon the jun2TRE site of its promoter. We further-
more show that lyso-PC can phosphorylate cyclic AMP re-
sponse element binding protein (CREB), which is thereby
bound to the jun2TRE site of the c-jun promoter.
2. Materials and methods
2.1. Reagents
Lysophosphatidylcholine (1-palmitoyl) was obtained from Avanti
Polar Lipids. Antibodies directed to c-Jun (rabbit polyclonal IgG),
JunB (goat polyclonal IgG), JunD (goat polyclonal IgG), c-Fos
(goat polyclonal IgG), activating transcription factor 2 (ATF-2) (rab-
bit polyclonal IgG) and CREB (rabbit polyclonal IgG) were obtained
from Santa Cruz Biotechnology. A polyclonal rabbit antibody speci¢c
for a phosphorylated (Ser-133) form of CREB (phospho-Ser133-
CREB) was from Upstate Biotechnology. The gel shift assay system,
pGL2 promoter vector, pRL-SV40 vector, dual-luciferase reporter
assay system were obtained from Promega. [Q-32P]ATP and [K-32P]-
dCTP were purchased from Amersham.
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2.2. Cell culture
Bovine aortic endothelial cells (BAEC) were harvested from bovine
aortas by scraping with a glass coverslip and cultured in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal
calf serum (FCS), 100 U/ml of penicillin and 100 Wg/ml of streptomy-
cin, and were grown in an atmosphere of 95% air, 5% CO2 at 37‡C.
Con£uent BAEC with passage numbers between 5 and 20 were serum
starved for 24 h and used for experiments.
2.3. Plasmid constructs
A 1590-bp fragment of the c-jun promoter was subcloned into
promoterless pGL-2 luciferase plasmid. Unidirectional deletion mu-
tants were made in the forward orientation promoter constructs:
3730/+850 Jun-Luc, 3268/+850 Jun-Luc, 3127/+850 Jun-Luc, 376/
+850 Jun-Luc and 326/+850 Jun-Luc were made. Each deleted dou-
ble-stranded DNA fragment was subcloned into the SmaI/XhoI site of
pGL2 promoter vector (Promega). Site-speci¢c mutagenesis of the
jun2TRE site was created by an overlapping PCR procedure [25,26].
The AP-1 site, 3191 ATTACCTCATC 3181, was changed to 3191
TGGACCTCGAG 3181 (mAP-1 Jun-Luc). The jun2TRE site, 371
TGACAT 366, was changed to 371 ATCCAC 366 (mjun2TRE Jun-
Luc), as described by Stein et al. and Angel [27,28]. Each mutated
double-stranded DNA fragment was subcloned into the MluI/BglII
site of the pGL2 promoter vector. Nucleotide sequences of these mu-
tant constructs were examined by the dideoxy chain termination meth-
od.
2.4. DNA transfection and luciferase assay
BAEC were transfected with 2Wg of Jun-Luc and 50 ng of pRL-
SV40 plasmid (Promega) by the lipofection method. Eight hours after
transfection, cells were washed with PBS and replaced with DMEM
with 1% FCS, and grown to con£uence and near quiescence (3^4 days
after transfection). After reaching con£uence, BAEC were incubated
for 2 h with lyso-PC (15 WM) in serum-free DMEM, subsequently
incubated with DMEM in the absence of lyso-PC for an additional
6 h. Fire£y and Renilla luciferase activities in BAEC lysates were
measured using the dual-luciferase reporter assay system (Promega).
Luciferase activities were normalized for protein concentrations of cell
lysates. Transfection e⁄ciencies of these plasmid constructs, which
were evaluated by Renilla luciferase activities, were not signi¢cantly
di¡erent between lyso-PC-treated and sham-treated BAEC.
2.5. Nuclear protein extraction
Nuclear protein extracts were prepared by the method of Sadowski
and Gilman [29]. In brief, BAEC were washed twice with ice-cold
PBS, once with PBS containing 1 mM Na3VO4 and 5 mM NaF
(PBS+V+F), and once with hypotonic bu¡er which consisted of 20
mM HEPES, pH 7.9, 20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7,
1 mM EDTA, 1 mM ethylene glycol tetraacetic acid (EGTA), 1 mM
DTT, 0.5 mM PMSF, 1 Wg/ml of leupeptin, 4 kallikrein inhibitor units
(KIU)/ml of aprotinin. Cells were then lysed with ice-cold hypotonic
bu¡er supplemented with 0.2% Nonidet P-40 (NP-40). Cell lysates
were centrifuged at maximum speed for 20 s, and the pelleted nuclei
were resuspended in hypotonic bu¡er with 420 WM NaCl and 20%
glycerol added and rocked gently for 30 min at 4‡C. Soluble extracted
nuclear proteins were isolated by centrifugation at maximum speed
for 20 min, and the supernatant (nuclear extract) was stored at
380‡C.
2.6. Gel shift assay
Gel shift assays were performed as described by Stein et al. [30]. In
brief, nuclear extracts (10 Wg of protein) were incubated on ice for 15
min with 2 Wg of poly (dIWdC)Wpoly (dIWdC) in binding bu¡er (10 mM
Tris, pH 7.9, 0.5 mM EDTA, 10% glycerol, 1 mM DTT, BSA) and
then incubated with double-stranded 32P-labeled oligonucleotides con-
taining the jun2TRE binding sequence for 20 min at room temper-
ature. The jun2TRE probe was made by annealing 5P-AGCTGCAT-
TACCTCATCCC-3P (3194 to 3179 of the c-jun promoter underlined
and core element in bold) and 5P-GATCGGGATGAGGTAATGCT-
3P. The mutant jun2TRE by annealing 5P-AGCTAGCTGGACCTC-
GAGCC-3P (core element in bold, mutated site underlined) and 5P-
GGCTCGAGGTCCAGCTAGCT-3P [24]. Nuclear extract-oligonu-
cleotide mixtures were then subjected to electrophoresis through 5%
(w/v) polyacrylamide gels containing 10% glycerol. Gels were dried,
and analyzed by Fujix Bioimage Analyzer BAS2000 (Fuji Photo
Film). Competition experiments were preincubating the extracts with
unlabeled jun2TRE or mutated jun2TRE oligonucleotides for 5 min.
Labeled oligonucleotide was then added for 20 min prior to electro-
phoresis. Antibody supershift assays were performed by adding the
appropriate antibody to the extract after a 20-min preincubation of
extract with labeled oligonucleotide. After 4 h at 4‡C, samples were
subjected to electrophoresis.
2.7. Western blot analysis
BAEC were washed twice with ice-cold PBS and lysed with lysis
bu¡er containing 20 mM Tris (pH 7.4), 10 mM EDTA, 60 mM L-
glycerophosphatase, 10 mM MgCl2, 1.0% Triton X-100, 1 mM so-
dium vanadate, 1 mM Pefabloc SC, 1 Wg/ml leupeptin and 0.1 U/ml
aprotinin. Protein concentrations were determined by the Bradford
method. Equal protein concentrations of the total cell lysates were
subjected to SDS-polyacrylamide (8%) gel electrophoresis, and elec-
troblotted onto nitrocellulose membranes (ECL, Amersham, UK).
Membranes were incubated with optimal concentrations of a rabbit
polyclonal antibody directed to phosphorylated CREB, and subse-
quently with peroxidase-conjugated anti-rabbit IgG (Amersham).
Bands were visualized by ECL reagents (Amersham).
Fig. 1. Lyso-PC stimulates transcription of c-jun promoter-luciferase
fusion genes. Fusion gene constructs consisting of the c-jun pro-
moter linked to the luciferase gene, including serial deletion mu-
tants, were constructed as indicated (A). BAECs were transiently
transfected with these c-jun promoter-luciferase fusion gene con-
structs, and subsequently treated with or without lyso-PC (15 WM)
for 2 h. After incubation without lyso-PC for an additional 6 h, the
luciferase activities were measured. Each value (fold increase in luci-
ferase activities in lyso-PC-treated BAEC as compared with BAEC
treated without lyso-PC) is indicated as mean þ S.D. from six inde-
pendent experiments.
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3. Results
3.1. The jun2TRE site in the c-jun promoter is crucial for lyso-
PC-induced transcription of the c-jun gene
To gain insights into the molecular mechanisms involved in
lyso-PC-induced transcription of the c-jun gene, a 1580-bp
fragment (3730/+850) of the c-jun promoter, as well as those
containing serial 5P deletion mutations (Fig. 1A), was linked
to a luciferase reporter gene and transiently transfected into
BAEC. After treatment with or without lyso-PC, luciferase
activities were measured. As shown in Fig. 1B, lyso-PC treat-
ment resulted in 12.9 þ 5.20-fold and 12.2 þ 4.41-fold increases
in luciferase activities in BAEC transfected with 3730/+850
Jun-Luc (the full length 1580-bp c-jun promoter) and 3268/
+850 Jun-Luc, respectively. In contrast, 3127/+850 Jun-Luc
and 376/+850 Jun-Luc, which lack the jun2TRE site, showed
2.97 þ 0.68-fold and 3.72 þ 0.93-fold increases in lyso-PC-in-
duced luciferase activities, respectively. 327/+850 Jun-Luc,
which lacks both jun2TRE and AP-1 sites, did not show
any signi¢cant transcriptional activation induced by lyso-PC
(Fig. 1B).
Since jun2TRE and AP-1 binding sites are located in these
lyso-PC responsive elements, we constructed c-jun promoter-
luciferase fusion genes containing point mutations in
jun2TRE and AP-1 sites. These constructs, designated
Fig. 2. Lyso-PC-induced transcription of the c-jun gene depends
upon jun2TRE and AP-1 sites of the promoter. Fusion gene con-
structs that consist of the c-jun promoter linked to the luciferase
gene, including point mutations in the jun2TRE and AP-1 sites,
were constructed as described in Section 2. BAEC were transiently
transfected with these c-jun promoter-luciferase fusion gene con-
structs, and subsequently treated with or without lyso-PC (15 WM)
for 2 h. After incubation without lyso-PC for an additional 6 h, the
luciferase activities were measured. Each value (fold increase in luci-
ferase activities in lyso-PC-treated BAEC as compared with BAEC
treated without lyso-PC) is indicated as mean þ S.D. from six inde-
pendent experiments.
C
Fig. 3. Lyso-PC stimulates CREB binding to the jun2TRE site. Gel
shift assays were performed using nuclear extracts prepared from
BAEC treated with 15 WM of lyso-PC for the indicated time periods
(A). Nuclear extracts obtained from BAEC stimulated with 15 WM
of lyso-PC for 15 min were incubated with radiolabeled jun2TRE
binding oligonucleotide in the presence or absence (3) of 10-fold
(10U) or 50-fold (50U) excess amounts of unlabeled jun2TRE oli-
gonucleotide, or a 50-fold excess amount of unlabeled mutant
jun2TRE oligonucleotide or AP-1 oligonucleotide (B). Nuclear ex-
tracts obtained from BAEC treated with 15 WM of lyso-PC for 15
min were preincubated with antibodies directed against c-Fos, c-Jun,
phosphorylated c-Jun, JunB, JunD, ATF-2, CREB, or non-immune
IgG, followed by incubation with radiolabeled jun2TRE oligonu-
cleotide probe and gel electrophoresis, followed by electrophoresis
and autoradiography (C). Jun2TRE binding is indicated by the
upper arrow, and unbound oligonucleotide probe is indicated by the
lower arrow. A representative ¢gure from four independent experi-
ments is shown.
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jun2TRE-mut and AP-1-mut, resulted in 70.3% and 30.6%
reductions in lyso-PC-induced luciferase activities, respectively
(Fig. 2). A c-jun promoter-luciferase construct that contains
point mutations in both the jun2TRE and AP-1 sites
(jun2TRE-mut+AP-1-mut) exhibited a more potent inhibitory
action (88.8% reduction) on lyso-PC-induced transcription
(Fig. 2). These results demonstrate that both jun2TRE and
AP-1 sites are essential for c-jun gene transcription induced by
lyso-PC; however, the jun2TRE site appears to play a major
role in this process when compared to the AP-1 site.
3.2. Nuclear extracts from lyso-PC-activated BAEC bind to
jun2TRE sites
To examine whether certain transcription factors can bind
to the jun2TRE site in the c-jun promoter in response to lyso-
PC, gel shift assays were performed, using radiolabeled oligo-
nucleotides with the jun2TRE sequence, on nuclear extracts
isolated from lyso-PC-treated BAEC. As shown in Fig. 3A,
lyso-PC induced jun2TRE shift bands in a time-dependent
manner. Shift bands with jun2TRE oligonucleotides were de-
tectable after 15 min, peaked at 30 min, and declined after
1 h. These shift bands elicited by lyso-PC appeared to be spe-
ci¢c, because preincubation of the nuclear extracts with unla-
beled jun2TRE oligonucleotides dose-dependently abolished
jun2TRE shift bands (Fig. 3B).
To identify molecules that bind to the jun2TRE site in
response to lyso-PC, nuclear extracts were preincubated with
antibodies directed to known transcription factors, and sub-
sequently gel shift assays were carried out. Preincubation with
an antibody for CREB, but not for c-Jun, JunB, JunD, c-Fos
or ATF-2, abolished the retarded band by jun2TRE oligonu-
cleotides (Fig. 3C). Taken together, binding of CREB to the
jun2TRE in the c-jun promoter is involved in lyso-PC-induced
transcription of the c-jun gene.
3.3. Phosphorylation of CREB by lyso-PC
Previous studies have shown that Ser-133 of CREB can be
phosphorylated and thereby bind to the cyclic AMP response
element (CRE) of the chromogranin A promoter [31]. There-
fore, we sought to de¢ne whether lyso-PC can phosphorylate
CREB and thereby bind to the jun2TRE site. Immunoblotting
with polyclonal antibodies directed to phospho-Ser133-CREB
demonstrated that lyso-PC phosphorylates CREB in a time-
dependent fashion (Fig. 4). Phosphorylation of CREB was
detectable at 15 min after lyso-PC treatment, and remained
for at least 2 h (Fig. 4). This time course of CREB phospho-
rylation by lyso-PC appears to be correlated with the time
course of the DNA binding to the jun2TRE site (Fig. 3A).
4. Discussion
Lyso-PC, a bioactive phospholipid relevant to atherogenesis
and in£ammation, has been shown to stimulate transcription
of a variety of genes [5^11]. We have demonstrated, for the
¢rst time, that lyso-PC can stimulate phosphorylation of
CREB and transactivate the jun2TRE site of the c-jun pro-
moter, which appears to be a major transcriptional regulatory
mechanism in lyso-PC-induced c-jun gene transcription. In
accordance with previous studies [20], lyso-PC also phospho-
rylates c-Jun and thereby activates the AP-1 site, which ap-
pears to be another transcriptional regulatory pathway in-
volved in lyso-PC-induced transcription of the c-jun gene.
These two pathways elicited by lyso-PC appear to be neces-
sary for lyso-PC-induced transcription of c-jun, as shown by
the promoter-reporter gene assay. These mechanisms may also
be involved in other endothelial gene expression whose tran-
scriptional regulation depends upon these two factors.
Although c-Jun and ATF-2 have been shown to bind to the
jun2TRE site in the c-jun promoter in rat kidney cells after
ischemia and reperfusion [24], our gel shift assays demon-
strated that CREB, but not ATF-2 or c-Jun, could bind to
the jun2TRE site in the c-jun promoter in lyso-PC-activated
BAEC. A previous report by Fang et al. has shown that lyso-
PC activates JNK, and thereby stimulates AP-1-dependent
gene transcription in Rat-1 and HeLa cells [19]. Our studies
also have shown that lyso-PC activates JNK, as well as ERK,
in BAEC [19], which can subsequently stimulate phosphoryl-
ation of c-Jun.
Involvement of protein kinase C (PKC) has been implicated
in lyso-PC-induced signal transduction [15]. Our previous
studies, however, showed that neither lyso-PC-induced expres-
sion of ICAM-1 or PDGF-B chain, nor tyrosine phospho-
rylation of PECAM-1 depends upon PKC activation [21,22].
Furthermore, activation of JNK by lyso-PC appears to be
independent of PKC [19,20]. Involvement of PKC in lyso-
PC-induced phosphorylation of CREB remains to be deter-
mined; however, lyso-PC-induced phosphorylation of c-Jun,
and subsequent transcriptional activation of the c-jun gene, as
well as other jun and fos gene family members, may also be
independent of PKC activation.
In addition to jun family genes, lyso-PC can also induce
expression of c-fos in BAEC (data not shown) as well as in
cultured vascular smooth muscle cells [32]. Phosphorylation of
CREB, as well as activation of serum response factor (SRF),
has been implicated in transcription activation of the c-fos
gene induced by various biological stimuli [33,34]. Phospho-
rylation of CREB by lyso-PC, therefore, may be responsible
for lyso-PC-induced transcription of c-fos. Furthermore, SRF
might also be involved in c-fos gene expression elicited by
lyso-PC. Further studies would be necessary to clarify the
transcriptional regulatory mechanisms involved in lyso-PC-in-
duced c-fos gene expression.
Which signal transduction cascades are involved in up-
stream of phosphorylation of c-Jun and CREB? Previous
studies have shown that small GTP binding proteins, such
as Rac/cdc42 [35] and Ras [36,37], and MAP kinase pathways,
including JNK and ERK [36,38], are involved in upstream of
c-Jun and CREB phosphorylation, respectively. p38 MAP
kinase has also been implicated in upstream of both c-jun
and CREB phosphorylation [39]. Since lyso-PC can activate
JNK [18,19] and ERK [18], studies are in progress in our
Fig. 4. Phosphorylation of CREB by lyso-PC. BAEC were treated
with or without 15 WM of lyso-PC for the indicated time periods,
and immunoblotting was performed using antibody directed to
phosphorylated CREB.
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laboratory to determine whether lyso-PC can active these
small GTP binding proteins.
In summary, the present study provides evidence, for the
¢rst time, that lyso-PC can phosphorylate CREB, which con-
sequently transactivates jun2TRE sites in the c-jun promoter.
Lyso-PC, therefore, may also transcriptionally induce other
endothelial genes relevant to atherogenesis and in£ammation,
whose transcriptional regulation depends upon these factors.
Further studies with transcriptional regulation and upstream
signal transduction cascades elicited by lyso-PC may provide
new insights to understand the biological actions of this active
phospholipid.
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